key: cord-0698206-6r8pvgir
authors: Makowska, Joanna; Styrzyński, Filip
title: Between COVID-19 severity and its prevention – what should rheumatologists be aware of?
date: 2021-02-28
journal: Reumatologia
DOI: 10.5114/reum.2021.103941
sha: 4d4f1be799ad9f44468db0408c5e2108dcdbc923
doc_id: 698206
cord_uid: 6r8pvgir

nan

and moderate/high activity of the rheumatic disease. The use of higher doses of prednisolone (> 10 mg/day), rituximab, sulfasalazine and some immunosuppressive drugs (azathioprine, cyclophosphamide, cyclosporine, mycophenolate and tacrolimus) was considered as an iatrogenic risk factor which increases the risk of death. Interestingly, the lack of DMARD treatment was associated with higher death risk compared to patients on metho trexate. Use of other biologicals or targeted synthetic DMARDs did not result in increased death risk. Also, in the study of Marques et al. [4] from Brazil, patients receiving high doses of immunosuppression (methylprednisolone or cyclophosphamide) had an increased risk of fatal outcomes, while treatment with TNF inhibitors seemed to have a protective role.

To sum up, the strongest risk factors for an unfavourable outcome are the same as in the general population, including advanced age, male sex and comorbidities such as diabetes, chronic lung disease or cardiovascular disease. Due to prolonged inflammation, autoimmune status and iatrogenic factors (e.g. chronic glucocorticosteroids treatment) patients with RMD and autoimmune systemic conditions are additionally prone to develop comorbidities associated with the elevated risk of a severe course of COVID-19 [5] .

These findings support current guidelines of EULAR and other rheumatological societies, emphasizing the importance of tight control of the disease activity in the COVID-19 era. Unfortunately, according to research from Poland, problems with access to both primary and outpatient health care experienced by many patients resulted in worsening of the rheumatic disease in 2020. Despite initial enthusiasm towards the introduction of telemedicine [6] , the rating of its usefulness dropped significantly after half a year of experience [article in press].

What seems very interesting is that the outcomes of COVID-19 treatments in RMD patients have changed over time. In the study of Jorge et al. [7] two cohorts of rheumatic patients infected with SARS-CoV-2 were com-Joanna Makowska, Filip Styrzyński Reumatologia 2021; 59/1 pared. The early cohort (infections in the spring of 2020) had higher risk of hospitalization, mechanical ventilation, intensive care unit admission and fatal outcome compared to the late cohort (infections during summer months). These differences are multifactorial, including better testing and earlier diagnosis, the learning curve of medical staff, as well as the possible result of implementing remdesivir, dexamethasone or tocilizumab in the treatment strategies.

Since the outbreak of the pandemic, the race towards development of an effective and well-tolerated vaccine has started. Many rheumatological patients are eager to receive the COVID-19 vaccine, although the involvement of such individuals in the studies was rather incidental. Definitely none of the currently available or forthcoming vaccines in the EU should be even associated with a theo retical risk for infection amongst immunosuppressed patients, but their effectiveness has not yet been evaluated. The guidelines of rheumatological societies worldwide are mostly consistent, with some minor differences, such as rescheduling rituximab therapy. Nevertheless, all the authors agree on the favourable risk profile of the vaccinations. Some conclusions on immunogenicity might be therefore encouraged by the previous research on influenza and pneumococcal vaccines.

Subesinghe et al. [8] stated that the humoral response was preserved amongst methotrexate or TNFi patients to the influenza vaccine, reduced in methotrexate, but not the TNFi group towards 6B/23F pneumococcal serotype, and was limited in the combination of methotrexate/TNFi to both vaccines. On the other hand, Park et al. [9] found in a randomized controlled trial that 2-week discontinuation of methotrexate, following vaccination of patients with rheumatoid arthritis, improves the humoral response to the influenza vaccine without exacerbation of the disease activity. According to Hua et al. [10] rituximab reduced the immunological response to both the influenza and pneumococcal vaccine. Other popular DMARDs do not seem to have a major influence, although large prospective studies are needed.

Although initially possible increased risk for severe allergic reactions towards COVID-19 vaccines was considered, the current data from the US (as of January 18 th ) describe anaphylaxis as a rare event (4.7 and 2.5 cases/ million for Pfizer and Moderna respectively), without any fatal cases reported [11] . According to an EAACI statement, there is no contraindication to administer COVID-19 vaccines under appropriate conditions apart from a history of an allergic reaction to any of the product components [12] .

In the light of recently published data on probable higher risk of a severe course of COVID-19 infection in rheumatic patients, vaccination should be widely recom mended, as up to now this seems to be a safe and effective way to prevent health decline.

The authors declare no conflict of interest.

COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry

COVID-19: What Do Rheumatologists Need to Know?

The attitude of Polish rheumatology patients towards telemedicine in the age of the COVID-19 pandemic

Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study

A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and metaanalysis

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US -December 14

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines